Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · IEX Real-Time Price · USD
1.170
+0.020 (1.74%)
At close: Jul 19, 2024, 4:00 PM
1.220
+0.050 (4.27%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Clearside Biomedical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CLSD stock have an average target of 4.60, with a low estimate of 4.00 and a high estimate of 5.00. The average target predicts an increase of 293.16% from the current stock price of 1.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLSD stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $5 | Buy | Initiates | $5 | +327.35% | Jun 25, 2024 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +241.88% | May 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +327.35% | May 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +412.82% | Mar 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +327.35% | Mar 13, 2024 |
Financial Forecast
Revenue This Year
594.15K
from 8.23M
Decreased by -92.78%
Revenue Next Year
4.27M
from 594.15K
Increased by 618.34%
EPS This Year
-0.58
from -0.53
EPS Next Year
-0.62
from -0.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.3M | 16.9M | 34.3M | 126.5M | 214.8M |
| Avg | 594,150 | 4.3M | 22.0M | 78.6M | 145.5M |
| Low | 196,000 | n/a | 10.2M | 53.9M | 104.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -84.0% | 2,751.6% | 703.3% | 475.9% | 173.4% |
| Avg | -92.8% | 618.3% | 414.5% | 257.8% | 85.3% |
| Low | -97.6% | - | 138.8% | 145.5% | 33.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.53 | -0.59 | -0.78 | 0.60 | 1.43 |
| Avg | -0.58 | -0.62 | -0.88 | 0.15 | 0.90 |
| Low | -0.66 | -0.65 | -1.06 | -0.26 | 0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 833.3% |
| Avg | - | - | - | - | 490.0% |
| Low | - | - | - | - | 162.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.